Recent study discovered that MTA1 complex including the trans-acting factor IFI16 and class II HDACs was recruited to the ERpro315 region of the ERα promoter, resulting in repression of ERα expression and generation of TAM resistance in MDA-MB-231 cells, highlighting that targeting the MTA1-IFI16 repressor complex may provide an alternative way for sensitizing ERα− breast cancer cells to TAM-based chemotherapies [17]. Here, IFI16 is linked to breast cancer.